Protox receives funding from NRC to develop lung cancer drug

09-Jun-2005

Protox Therapeutics Inc. announced that it has received a financial contribution of up to $340,000 from the National Research Council ('NRC') Industrial Research Assistance Program ('IRAP'). The NRC has committed this money to the Company to support its development of Lung-H1, a therapeutic toxin for the treatment of non small cell lung cancer. The contribution is non-repayable.

"We are pleased to be the recipient of the IRAP funding in support of our lung cancer program," said Dr. Fahar Merchant, President & CEO of the Company. "On April 5, 2005 we announced that the Company is moving forward with licensing negotiations for the Lung H1 technology from the NRC Institute of Biological Sciences and the University of Victoria Innovation and Development Corporation. This funding will help to drive the development of this promising technology".

Protox has established a partnership with the NRC Institute of Biological Sciences to produce and test cancer therapeutics that have been created by linking Aerolysin to single chain antibodies that bind to cancer cells. The first application of this approach is the development of Lung-H1 for the treatment of non small cell lung cancer (NSCLC) which accounts for approximately 75% of all lung cancers. Lung cancer remains the most common malignancy with an estimated 1.04 million new cases and 921,000 deaths each year worldwide. Patients with NSCLC have poor prognosis and most patients do not respond satisfactorily to treatment.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous